Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT ID: NCT00866697
Last Updated: 2021-02-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
940 participants
INTERVENTIONAL
2009-05-26
2017-08-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women
NCT01227928
Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors
NCT00561795
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
NCT01610206
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
NCT01468909
Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin
NCT00369954
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
matched placebo tablet administered orally once daily for up to 24 months
Placebo
Matching placebo 800 mg tablet daily, for 104 weeks (24 months).
Pazopanib
Pazopanib tablet administered orally at 800 mg once daily for up to 24 months
Pazopanib
Pazopanib 800 mg tablet daily for 104 weeks (24 months)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pazopanib
Pazopanib 800 mg tablet daily for 104 weeks (24 months)
Placebo
Matching placebo 800 mg tablet daily, for 104 weeks (24 months).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 18 years old.
* Histologically confirmed, FIGO stage II-IV epithelial ovarian, fallopian tube or primary peritoneal carcinoma that was treated with surgical debulking and at least five cycles of platinum-taxane doublet chemotherapy.
* Study randomization at least 3 weeks and not more than 12 weeks from the date of the last chemotherapy dose, and all major toxicities from the previous chemotherapy must have resolved.
* No evidence of disease progression
* ECOG status of 0 or 2
* Able to swallow and retain oral medication.
* Adequate hematologic, hepatic, and renal system function as follows:
Hematologic
* Absolute neutrophil count (ANC) at least 1.5 X 10\^9/L
* Hemoglobin at least 9 g/dL (or 5.59 mmol/L)
* Platelets at least 100 X 10\^9/L
* Prothrombin time (PT) or international normalized ratio (INR) up to 1.2 X ULN
* Activated partial thromboplastin time (aPTT) up to 1.2 X ULN Hepatic
* Total bilirubin up to 1.5 X ULN
* AST and ALT up to 2.5 X ULN Renal
* Serum creatinine up to 1.5 mg/dL
Or, if greater than 1.5 mg/dL:
Calculated creatinine clearance at least 50 mL/min Urine Protein
* Urine protein is 0, trace, or +1 determined by dipstick urinalysis, or \< 1.0 gram determined by 24- hour urine protein analysis.
* Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) OR childbearing potential, and agrees to use adequate contraception.
Exclusion Criteria
* Synchronous primary endometrial carcinoma, or a past history of primary endometrial carcinoma, are excluded unless certain conditions are met.
* Clinically significant gastrointestinal abnormalities
* Prolongation of corrected QT interval (QTc) \> 480 msecs
* History of any one or more cardiovascular conditions within the past 6 months prior to randomization
* Cardiac angioplasty or stenting
* Myocardial infarction
* Unstable angina
* Symptomatic peripheral vascular disease
* Class III or IV congestive heart failure
* Poorly controlled hypertension
* History of cerebrovascular accident (including transient ischemic attacks), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months prior to randomization
* Major surgery (including interval debulking) or trauma within 28 days, or minor surgical procedures within 7 days, prior to randomization, or has any non-healing wound, fracture, or ulcer.
* Evidence of active bleeding or bleeding diathesis.
* Hemoptysis within 6 weeks prior to randomization.
* Endobronchial metastases.
* Serious and/or unstable pre-existing medical (e.g., uncontrolled infection), psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.
* Investigational or anti-VEGF anticancer therapy prior to study randomization.
* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib
* Invasive malignancies that showed activity of disease within 5 years prior to randomization
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
Anaheim, California, United States
Novartis Investigative Site
Baldwin Park, California, United States
Novartis Investigative Site
Bellflower, California, United States
Novartis Investigative Site
Duarte, California, United States
Novartis Investigative Site
Fontana, California, United States
Novartis Investigative Site
Hayward, California, United States
Novartis Investigative Site
Irvine, California, United States
Novartis Investigative Site
Long Beach, California, United States
Novartis Investigative Site
Los Angeles, California, United States
Novartis Investigative Site
Los Angeles, California, United States
Novartis Investigative Site
Los Angeles, California, United States
Novartis Investigative Site
Oakland, California, United States
Novartis Investigative Site
Ontario, California, United States
Novartis Investigative Site
Orange, California, United States
Novartis Investigative Site
Panorama City, California, United States
Novartis Investigative Site
Riverside, California, United States
Novartis Investigative Site
Roseville, California, United States
Novartis Investigative Site
Sacramento, California, United States
Novartis Investigative Site
Sacramento, California, United States
Novartis Investigative Site
San Diego, California, United States
Novartis Investigative Site
San Diego, California, United States
Novartis Investigative Site
San Francisco, California, United States
Novartis Investigative Site
San Jose, California, United States
Novartis Investigative Site
Santa Clara, California, United States
Novartis Investigative Site
South San Francisco, California, United States
Novartis Investigative Site
Vallejo, California, United States
Novartis Investigative Site
Walnut Creek, California, United States
Novartis Investigative Site
Woodland Hills, California, United States
Novartis Investigative Site
Augusta, Georgia, United States
Novartis Investigative Site
Morristown, New Jersey, United States
Novartis Investigative Site
New York, New York, United States
Novartis Investigative Site
New York, New York, United States
Novartis Investigative Site
The Bronx, New York, United States
Novartis Investigative Site
Houston, Texas, United States
Novartis Investigative Site
Annandale, Virginia, United States
Novartis Investigative Site
Camperdown, New South Wales, Australia
Novartis Investigative Site
Liverpool, New South Wales, Australia
Novartis Investigative Site
Randwick, New South Wales, Australia
Novartis Investigative Site
Waratah, New South Wales, Australia
Novartis Investigative Site
Herston, Queensland, Australia
Novartis Investigative Site
South Brisbane, Queensland, Australia
Novartis Investigative Site
Adelaide, South Australia, Australia
Novartis Investigative Site
Hobart, Tasmania, Australia
Novartis Investigative Site
Malvern, Victoria, Australia
Novartis Investigative Site
Parkville, Victoria, Australia
Novartis Investigative Site
Wodonga, Victoria, Australia
Novartis Investigative Site
Nedlands, Western Australia, Australia
Novartis Investigative Site
Melbourne, , Australia
Novartis Investigative Site
Graz, , Austria
Novartis Investigative Site
Graz, , Austria
Novartis Investigative Site
Innsbruck, , Austria
Novartis Investigative Site
Klagenfurt, , Austria
Novartis Investigative Site
Korneuburg, , Austria
Novartis Investigative Site
Krems, , Austria
Novartis Investigative Site
Leoben, , Austria
Novartis Investigative Site
Linz, , Austria
Novartis Investigative Site
Linz, , Austria
Novartis Investigative Site
Oberpullendorf, , Austria
Novartis Investigative Site
Vienna, , Austria
Novartis Investigative Site
Vienna, , Austria
Novartis Investigative Site
Vienna, , Austria
Novartis Investigative Site
Bonheiden, , Belgium
Novartis Investigative Site
Duffel, , Belgium
Novartis Investigative Site
Ghent, , Belgium
Novartis Investigative Site
Kortrijk, , Belgium
Novartis Investigative Site
Leuven, , Belgium
Novartis Investigative Site
Libramont, , Belgium
Novartis Investigative Site
Liège, , Belgium
Novartis Investigative Site
Namur, , Belgium
Novartis Investigative Site
Ostend, , Belgium
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Nanjing, Jiangsu, China
Novartis Investigative Site
Shenyang, Liaoning, China
Novartis Investigative Site
Jinan, Shandong, China
Novartis Investigative Site
Hangzhou, Zhejiang, China
Novartis Investigative Site
Hangzhou, Zhejiang, China
Novartis Investigative Site
Beijing, , China
Novartis Investigative Site
Beijing, , China
Novartis Investigative Site
Beijing, , China
Novartis Investigative Site
Beijing, , China
Novartis Investigative Site
Shanghai, , China
Novartis Investigative Site
Shanghai, , China
Novartis Investigative Site
Tianjin, , China
Novartis Investigative Site
Aalborg, , Denmark
Novartis Investigative Site
Herlev, , Denmark
Novartis Investigative Site
Herning, , Denmark
Novartis Investigative Site
Koebenhavn Oe, , Denmark
Novartis Investigative Site
Angers, , France
Novartis Investigative Site
Avignon, , France
Novartis Investigative Site
Besançon, , France
Novartis Investigative Site
Bordeaux, , France
Novartis Investigative Site
Bordeaux, , France
Novartis Investigative Site
Bordeaux, , France
Novartis Investigative Site
Bourg-en-Bresse, , France
Novartis Investigative Site
Brest, , France
Novartis Investigative Site
Brive-la-Gaillarde, , France
Novartis Investigative Site
Caen, , France
Novartis Investigative Site
Clermont-Ferrand, , France
Novartis Investigative Site
Colmar, , France
Novartis Investigative Site
Dax, , France
Novartis Investigative Site
Grenoble, , France
Novartis Investigative Site
Grenoble, , France
Novartis Investigative Site
La Roche-sur-Yon, , France
Novartis Investigative Site
Le Chesnay, , France
Novartis Investigative Site
Le Mans, , France
Novartis Investigative Site
Lille, , France
Novartis Investigative Site
Lille, , France
Novartis Investigative Site
Lorient, , France
Novartis Investigative Site
Lyon, , France
Novartis Investigative Site
Marseille, , France
Novartis Investigative Site
Metz, , France
Novartis Investigative Site
Mont-de-Marsan, , France
Novartis Investigative Site
Montpellier, , France
Novartis Investigative Site
Montpellier, , France
Novartis Investigative Site
Mougins, , France
Novartis Investigative Site
Nancy, , France
Novartis Investigative Site
Nantes, , France
Novartis Investigative Site
Nice, , France
Novartis Investigative Site
Nîmes, , France
Novartis Investigative Site
Orléans, , France
Novartis Investigative Site
Paris, , France
Novartis Investigative Site
Paris, , France
Novartis Investigative Site
Paris, , France
Novartis Investigative Site
Paris, , France
Novartis Investigative Site
Paris, , France
Novartis Investigative Site
Paris, , France
Novartis Investigative Site
Perin Sur Mer, , France
Novartis Investigative Site
Périgueux, , France
Novartis Investigative Site
Pierre-Bénite, , France
Novartis Investigative Site
Reims, , France
Novartis Investigative Site
Rouen, , France
Novartis Investigative Site
Saint-Herblain, , France
Novartis Investigative Site
Saint-Priest-en-Jarez, , France
Novartis Investigative Site
Strasbourg, , France
Novartis Investigative Site
Strasbourg, , France
Novartis Investigative Site
Suresnes, , France
Novartis Investigative Site
Thonon-les-Bains, , France
Novartis Investigative Site
Vandœuvre-lès-Nancy, , France
Novartis Investigative Site
Esslingen am Neckar, Baden-Wurttemberg, Germany
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Novartis Investigative Site
Karlsruhe, Baden-Wurttemberg, Germany
Novartis Investigative Site
Karlsruhe, Baden-Wurttemberg, Germany
Novartis Investigative Site
Mannheim, Baden-Wurttemberg, Germany
Novartis Investigative Site
Mutlangen, Baden-Wurttemberg, Germany
Novartis Investigative Site
Reutlingen, Baden-Wurttemberg, Germany
Novartis Investigative Site
Schwäbisch Hall, Baden-Wurttemberg, Germany
Novartis Investigative Site
Tübingen, Baden-Wurttemberg, Germany
Novartis Investigative Site
Ulm, Baden-Wurttemberg, Germany
Novartis Investigative Site
Bayreuth, Bavaria, Germany
Novartis Investigative Site
Coburg, Bavaria, Germany
Novartis Investigative Site
Deggendorf, Bavaria, Germany
Novartis Investigative Site
Ebersberg, Bavaria, Germany
Novartis Investigative Site
Eggenfelden, Bavaria, Germany
Novartis Investigative Site
Fürth, Bavaria, Germany
Novartis Investigative Site
Munich, Bavaria, Germany
Novartis Investigative Site
Munich, Bavaria, Germany
Novartis Investigative Site
Munich, Bavaria, Germany
Novartis Investigative Site
Schweinfurt, Bavaria, Germany
Novartis Investigative Site
Darmstadt, Hesse, Germany
Novartis Investigative Site
Frankfurt am Main, Hesse, Germany
Novartis Investigative Site
Frankfurt am Main, Hesse, Germany
Novartis Investigative Site
Fulda, Hesse, Germany
Novartis Investigative Site
Kassel, Hesse, Germany
Novartis Investigative Site
Lich, Hesse, Germany
Novartis Investigative Site
Limburg an der Lahn, Hesse, Germany
Novartis Investigative Site
Marburg, Hesse, Germany
Novartis Investigative Site
Offenbach, Hesse, Germany
Novartis Investigative Site
Offenbach, Hesse, Germany
Novartis Investigative Site
Wiesbaden, Hesse, Germany
Novartis Investigative Site
Wiesbaden, Hesse, Germany
Novartis Investigative Site
Braunschweig, Lower Saxony, Germany
Novartis Investigative Site
Cuxhaven, Lower Saxony, Germany
Novartis Investigative Site
Georgsmarienhütte, Lower Saxony, Germany
Novartis Investigative Site
Gifhorn, Lower Saxony, Germany
Novartis Investigative Site
Goslar, Lower Saxony, Germany
Novartis Investigative Site
Göttingen, Lower Saxony, Germany
Novartis Investigative Site
Hanover, Lower Saxony, Germany
Novartis Investigative Site
Hanover, Lower Saxony, Germany
Novartis Investigative Site
Hanover, Lower Saxony, Germany
Novartis Investigative Site
Hildesheim, Lower Saxony, Germany
Novartis Investigative Site
Leer, Lower Saxony, Germany
Novartis Investigative Site
Lüneburg, Lower Saxony, Germany
Novartis Investigative Site
Oldenburg, Lower Saxony, Germany
Novartis Investigative Site
Salzgitter, Lower Saxony, Germany
Novartis Investigative Site
Wolfsburg, Lower Saxony, Germany
Novartis Investigative Site
Greifswald, Mecklenburg-Vorpommern, Germany
Novartis Investigative Site
Rostock, Mecklenburg-Vorpommern, Germany
Novartis Investigative Site
Bonn, North Rhine-Westphalia, Germany
Novartis Investigative Site
Bonn, North Rhine-Westphalia, Germany
Novartis Investigative Site
Bonn, North Rhine-Westphalia, Germany
Novartis Investigative Site
Bonn, North Rhine-Westphalia, Germany
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site
Detmold, North Rhine-Westphalia, Germany
Novartis Investigative Site
Dortmund, North Rhine-Westphalia, Germany
Novartis Investigative Site
Düsseldorf, North Rhine-Westphalia, Germany
Novartis Investigative Site
Essen, North Rhine-Westphalia, Germany
Novartis Investigative Site
Essen, North Rhine-Westphalia, Germany
Novartis Investigative Site
Essen, North Rhine-Westphalia, Germany
Novartis Investigative Site
Neuss, North Rhine-Westphalia, Germany
Novartis Investigative Site
Troisdorf, North Rhine-Westphalia, Germany
Novartis Investigative Site
Viersen, North Rhine-Westphalia, Germany
Novartis Investigative Site
Mainz, Rhineland-Palatinate, Germany
Novartis Investigative Site
Trier, Rhineland-Palatinate, Germany
Novartis Investigative Site
Chemnitz, Saxony, Germany
Novartis Investigative Site
Dresden, Saxony, Germany
Novartis Investigative Site
Dresden, Saxony, Germany
Novartis Investigative Site
Leipzg, Saxony, Germany
Novartis Investigative Site
Radebeul, Saxony, Germany
Novartis Investigative Site
Zwickau, Saxony, Germany
Novartis Investigative Site
Halle, Saxony-Anhalt, Germany
Novartis Investigative Site
Magdeburg, Saxony-Anhalt, Germany
Novartis Investigative Site
Magdeburg, Saxony-Anhalt, Germany
Novartis Investigative Site
Quedlinburg, Saxony-Anhalt, Germany
Novartis Investigative Site
Salzwedel, Saxony-Anhalt, Germany
Novartis Investigative Site
Flensburg, Schleswig-Holstein, Germany
Novartis Investigative Site
Kiel, Schleswig-Holstein, Germany
Novartis Investigative Site
Lübeck, Schleswig-Holstein, Germany
Novartis Investigative Site
Gera, Thuringia, Germany
Novartis Investigative Site
Nordhausen, Thuringia, Germany
Novartis Investigative Site
Suhl, Thuringia, Germany
Novartis Investigative Site
Berlin, , Germany
Novartis Investigative Site
Berlin, , Germany
Novartis Investigative Site
Berlin, , Germany
Novartis Investigative Site
Berlin, , Germany
Novartis Investigative Site
Hamburg, , Germany
Novartis Investigative Site
Hamburg, , Germany
Novartis Investigative Site
Hamburg, , Germany
Novartis Investigative Site
Hong Kong, , Hong Kong
Novartis Investigative Site
Kowloon, , Hong Kong
Novartis Investigative Site
Dublin, , Ireland
Novartis Investigative Site
Dublin, , Ireland
Novartis Investigative Site
Dublin, , Ireland
Novartis Investigative Site
Dublin, , Ireland
Novartis Investigative Site
Waterford, , Ireland
Novartis Investigative Site
Wilton, Cork, , Ireland
Novartis Investigative Site
Bari, Apulia, Italy
Novartis Investigative Site
Potenza, Basilicate, Italy
Novartis Investigative Site
Avellino, Campania, Italy
Novartis Investigative Site
Napoli, Campania, Italy
Novartis Investigative Site
Bologna, Emilia-Romagna, Italy
Novartis Investigative Site
Bologna, Emilia-Romagna, Italy
Novartis Investigative Site
Carpi (MO), Emilia-Romagna, Italy
Novartis Investigative Site
Faenza (RA), Emilia-Romagna, Italy
Novartis Investigative Site
Reggio Emilia, Emilia-Romagna, Italy
Novartis Investigative Site
Aviano (PN), Friuli Venezia Giulia, Italy
Novartis Investigative Site
Rome, Lazio, Italy
Novartis Investigative Site
Rome, Lazio, Italy
Novartis Investigative Site
Rome, Lazio, Italy
Novartis Investigative Site
Brescia, Lombardy, Italy
Novartis Investigative Site
Como, Lombardy, Italy
Novartis Investigative Site
Milan, Lombardy, Italy
Novartis Investigative Site
Milan, Lombardy, Italy
Novartis Investigative Site
Milan, Lombardy, Italy
Novartis Investigative Site
Milan, Lombardy, Italy
Novartis Investigative Site
Milan, Lombardy, Italy
Novartis Investigative Site
Monza, Lombardy, Italy
Novartis Investigative Site
Sondrio, Lombardy, Italy
Novartis Investigative Site
Varese, Lombardy, Italy
Novartis Investigative Site
Campobasso, Molise, Italy
Novartis Investigative Site
Turin, Piedmont, Italy
Novartis Investigative Site
Turin, Piedmont, Italy
Novartis Investigative Site
Palermo, Sicily, Italy
Novartis Investigative Site
Perugia, Umbria, Italy
Novartis Investigative Site
Vicenza, Veneto, Italy
Novartis Investigative Site
Ehime, , Japan
Novartis Investigative Site
Fukuoka, , Japan
Novartis Investigative Site
Hiroshima, , Japan
Novartis Investigative Site
Hiroshima, , Japan
Novartis Investigative Site
Hokkaido, , Japan
Novartis Investigative Site
Kagoshima, , Japan
Novartis Investigative Site
Miyagi, , Japan
Novartis Investigative Site
Numakunai, , Japan
Novartis Investigative Site
Osaka, , Japan
Novartis Investigative Site
Saitama, , Japan
Novartis Investigative Site
Tokyo, , Japan
Novartis Investigative Site
Tokyo, , Japan
Novartis Investigative Site
Tokyo, , Japan
Novartis Investigative Site
Tokyo, , Japan
Novartis Investigative Site
Tottori, , Japan
Novartis Investigative Site
Bergen, , Norway
Novartis Investigative Site
Oslo, , Norway
Novartis Investigative Site
Stavanger, , Norway
Novartis Investigative Site
Tromsø, , Norway
Novartis Investigative Site
Goyang-si, Gyeonggi-do, , South Korea
Novartis Investigative Site
Kangnam-Ku ,Seoul, , South Korea
Novartis Investigative Site
Seoul, , South Korea
Novartis Investigative Site
Seoul, , South Korea
Novartis Investigative Site
Seoul, , South Korea
Novartis Investigative Site
Alcorcon (Madrid), , Spain
Novartis Investigative Site
Barcelona, , Spain
Novartis Investigative Site
Barcelona, , Spain
Novartis Investigative Site
Barcelona, , Spain
Novartis Investigative Site
Barcelona, , Spain
Novartis Investigative Site
Cartagena (Murcia), , Spain
Novartis Investigative Site
Donostia / San Sebastian, , Spain
Novartis Investigative Site
Elche, , Spain
Novartis Investigative Site
Lleida, , Spain
Novartis Investigative Site
Madrid, , Spain
Novartis Investigative Site
Madrid, , Spain
Novartis Investigative Site
Madrid, , Spain
Novartis Investigative Site
Madrid, , Spain
Novartis Investigative Site
Madrid, , Spain
Novartis Investigative Site
Murcia (El Palmar), , Spain
Novartis Investigative Site
Palma de Mallorca, , Spain
Novartis Investigative Site
Pamplona, , Spain
Novartis Investigative Site
Sabadell (Barcelona), , Spain
Novartis Investigative Site
Santiago de Compostela, , Spain
Novartis Investigative Site
Terrassa, , Spain
Novartis Investigative Site
Valencia, , Spain
Novartis Investigative Site
Valencia, , Spain
Novartis Investigative Site
Zaragoza, , Spain
Novartis Investigative Site
Linköping, , Sweden
Novartis Investigative Site
Lund, , Sweden
Novartis Investigative Site
Stockholm, , Sweden
Novartis Investigative Site
Uppsala, , Sweden
Novartis Investigative Site
Taipei, , Taiwan
Novartis Investigative Site
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gaitskell K, Rogozinska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3.
Vergote I, du Bois A, Floquet A, Rau J, Kim JW, Del Campo JM, Friedlander M, Pignata S, Fujiwara K, Colombo N, Mirza MR, Monk BJ, Tsibulak I, Calvert PM, Herzog TJ, Hanker LC, Meunier J, Lee JY, Bologna A, Carrasco-Alfonso MJ, Harter P. Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2019 Nov;155(2):186-191. doi: 10.1016/j.ygyno.2019.08.024. Epub 2019 Sep 10.
Friedlander M, Rau J, Lee CK, Meier W, Lesoin A, Kim JW, Poveda A, Buck M, Scambia G, Shimada M, Hilpert F, King MT, Debruyne P, Bologna A, Malander S, Monk BJ, Petru E, Calvert P, Herzog TJ, Barrett C, du Bois A. Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy. Ann Oncol. 2018 Mar 1;29(3):737-743. doi: 10.1093/annonc/mdx796.
Pulford DJ, Harter P, Floquet A, Barrett C, Suh DH, Friedlander M, Arranz JA, Hasegawa K, Tada H, Vuylsteke P, Mirza MR, Donadello N, Scambia G, Johnson T, Cox C, Chan JK, Imhof M, Herzog TJ, Calvert P, Wimberger P, Berton-Rigaud D, Lim MC, Elser G, Xu CF, du Bois A. Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study. BMC Med Ethics. 2016 Oct 21;17(1):63. doi: 10.1186/s12910-016-0144-y.
Kim JW, Mahner S, Wu LY, Shoji T, Kim BG, Zhu JQ, Takano T, Park SY, Kong BH, Wu Q, Wang KL, Ngan HY, Liu JH, Wei LH, Mitrica I, Zhang P, Crescenzo R, Wang Q, Cox CJ, Harter P, du Bois A. Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study. Int J Gynecol Cancer. 2018 Jan;28(1):2-10. doi: 10.1097/IGC.0000000000000602.
Floquet A, Vergote I, Colombo N, Fiane B, Monk BJ, Reinthaller A, Calvert P, Herzog TJ, Meier W, Kim JW, del Campo JM, Friedlander M, Pisano C, Isonishi S, Crescenzo RJ, Barrett C, Wang K, Mitrica I, du Bois A. Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial. Gynecol Oncol. 2015 Jan;136(1):37-42. doi: 10.1016/j.ygyno.2014.11.074. Epub 2014 Nov 28.
du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014 Oct 20;32(30):3374-82. doi: 10.1200/JCO.2014.55.7348. Epub 2014 Sep 15.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-004672-50
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CPZP034C2301
Identifier Type: OTHER
Identifier Source: secondary_id
110655
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.